| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.05 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.099 | 0.05 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.08 | 0.05 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.06 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.06 |